Bexorg
Bexorg is a Yale-spinout CNS drug discovery platform that combines proprietary whole-human brain perfusion (BrainEx) with an AI engine (XO Digital/NeuroLens) to test therapeutics directly in human brain tissue, serving pharmaceutical and biotech partners seeking to reduce the 95%+ CNS clinical trial failure rate.
- Company typePrivate
- Founded2021
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Bexorg does
Bexorg is a private CNS drug discovery platform company founded in 2021 and spun out of Yale University research by Drs. Zvonimir Vrselja and Nenad Sestan. The company's core technology, BrainEx, is a proprietary whole-brain perfusion system that restores molecular activity in postmortem donated human brains, creating a uniquely translational model for testing therapeutics directly in physiologically intact human brain tissue. BrainEx is paired with an integrated AI stack (XO Digital / NeuroScale / NeuroLens) that ingests molecular, transcriptomic, proteomic, and metabolic data from each experiment to train predictive models, forming a closed-loop system of in-silico prediction and wet-lab validation.
The platform addresses the structural 95%+ CNS clinical trial failure rate by enabling pharmaceutical and biotech partners to test drug candidates (small molecules, biologics, viral vectors, LNPs) in human brain tissue across disease-relevant states including Alzheimer's and Parkinson's, generating target engagement, pharmacokinetic/pharmacodynamic, and biomarker data prior to clinical entry. Bexorg operates a B2B enterprise model with strategic research collaborations; its anchor customer Biohaven has used approximately 130 brains to advance two preclinical programs, and the company has additional collaborations with the University of Oxford / UK Medical Research Council and The Michael J. Fox Foundation.
Bexorg is headquartered in New Haven, Connecticut near Yale, with a secondary office in San Francisco, and operates a new robotic lab capable of processing up to 1,600 brains per year. As of January 2026 the company has 41 employees and $42.5 million in total funding, including a $23 million Series A led by Engine Ventures in October 2025. Revenue is generated through professional services and recurring partnership arrangements with enterprise pharma and biotech clients, with pricing not publicly disclosed.
Bexorg firmographics
Firmographics- Name
- Bexorg
- Legal name
- Bexorg, Inc.
- Website
- https://bexorg.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Bexorg is a Yale-spinout CNS drug discovery platform that combines proprietary whole-human brain perfusion (BrainEx) with an AI engine (XO Digital/NeuroLens) to test therapeutics directly in human brain tissue, serving pharmaceutical and biotech partners seeking to reduce the 95%+ CNS clinical trial failure rate.
- Ownership category
- akta.pro rank
Bexorg industry classification
Industry- Product category
- CNS Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Bexorg is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Bexorg business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Research Collaboration Services: Bexorg generates revenue through multi-program research collaborations with pharmaceutical companies. The company provides its whole-brain discovery platform to demonstrate target engagement, generate biomarkers, pharmacokinetic/pharmacodynamic data, and mechanistic insights to support preclinical development programs. Revenue comes from service fees for experiments and data generation.
- Strategic Partnership Programs: Collaborative partnerships where Bexorg delivers insights from drug testing on whole human brains, including analysis of pharmacokinetics, pharmacodynamics, and mechanism of action. May include co-development arrangements and milestone payments.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Bexorg product offering
Product offeringCore offering
Bexorg operates the Brainex Platform, an integrated drug discovery system that combines the BrainEx whole-brain perfusion technology—capable of restoring molecular activity in postmortem human brains—with AI engines (NeuroScale/NeuroLens/XO Digital) that translate experimental data into predictive models. The company sells research collaboration services to pharmaceutical and biotech partners, enabling them to test therapeutics directly in physiologically intact human brain tissue to generate pharmacokinetic, pharmacodynamic, and biomarker data for CNS drug development.
Product overview
Bexorg offers an integrated drug discovery platform called the Brainex Platform, which combines the BrainEx whole-brain perfusion system with NeuroScale experimental capabilities and the XO Digital AI engine. BrainEx restores molecular activity in postmortem human brains for direct drug testing, NeuroScale captures dynamic molecular data in real time, and XO Digital creates a closed-loop AI system that learns from experiments to generate predictive models. Together, these components aim to address the 95%+ CNS clinical trial failure rate by generating human-relevant data instead of relying on animal or cell models.
Differentiator
Problem solved
Functional benefit
Brands
- BrainEx: The proprietary whole-brain perfusion platform that restores molecular activity in donated whole-human brains, creating a translational model for clinically predictive data and drug discovery.
- XO Digital (NeuroScale)
- NeuroLens
Products and services
- Brainex Platform Integrated drug discovery platform that combines whole-brain perfusion experimentation with AI-driven predictive modeling, designed to generate clinically predictive human CNS data for pharmaceutical and biotech partners developing therapies for neurodegenerative and other neurological diseases.
- BrainEx Proprietary whole-brain perfusion platform that restores molecular activity in donated postmortem human brains, enabling systematic delivery of small molecules, biologics, viral vectors, and LNPs through the competent vascular system and blood-brain barrier for direct drug testing in physiologically intact human brain tissue.
- Research Collaboration Services
Quantifiable outcome
- Over 95% CNS clinical trial failure rate reduced through human brain testing
- +3 more outcomes
Companies that use Bexorg
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Bexorg technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Bexorg partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and strategic.
- The Michael J. Fox Foundation for Parkinson's ResearchcoreResearch grant awarded through the Targets to Therapies Initiative to identify translational biomarkers for TRPML1-targeted Parkinson's disease therapies. Bexorg leverages its postmortem whole-human brain platform to identify biomarkers that track drug activity in human brain tissue donated by people who lived with Parkinson's disease.
- BiohavencoreMulti-program research collaboration to identify, de-risk, and advance next-generation therapies for CNS disorders. Bexorg's whole-brain discovery platform is used to demonstrate target engagement in relevant cell types and tissues and generate novel biomarkers, pharmacokinetic and pharmacodynamic relationships, and other mechanistic data to support two preclinical development programs at Biohaven.
- University of OxfordstrategicPartnership with University of Oxford and UK Medical Research Council as part of collaborative effort to advance translational gene therapy development for neurological diseases.
- LifeNet HealthcoreOrgan procurement organization that provides high-quality, ethically sourced human biological materials for research. Supplies postmortem whole brains to Bexorg for drug testing.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Bexorg competitors and assessment
Company assessmentDirect peers
- Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning. Directly comparable to Bexorg in using AI/automation to generate proprietary experimental datasets and partner with pharma, though focused on image-based cellular assays rather than whole-brain tissue.
- Insitro: Machine-learning-enabled drug discovery platform that combines engineered human cell models with predictive models. Comparable as an AI-first biotech generating proprietary human-relevant datasets for pharma partnerships, especially in CNS and metabolic disease.
- Atomwise: AI-driven small molecule discovery company using structure-based deep learning to partner with pharma. Comparable as an AI-platform business that sells discovery collaborations to large pharma rather than developing assets solo, though Bexorg's wet-lab data engine is uniquely physical.
- InSilico Medicine: End-to-end AI drug discovery company combining generative chemistry, target identification, and clinical development. Comparable as an AI drug discovery platform with pharma partnerships and an in-house pipeline, and a leading indicator for the AI-platform biotech model Bexorg aspires to.
Broad incumbents
- Charles River Laboratories: Largest contract research organization providing preclinical and discovery services to pharma, including CNS animal models. Comparable as a high-touch preclinical services partner to pharma but lacks Bexorg's whole-human-brain and AI capabilities.
Emerging players
- Xaira Therapeutics: AI-native drug discovery startup founded in 2023 with over $1B in funding, applying foundation models to biology. Comparable as a well-capitalized AI-bio platform with a similar model of building proprietary biological data assets to power drug discovery partnerships.
- Organoid Therapeutics: Emerging CNS-focused biotech using patient-derived organoid models for drug discovery. Comparable as an alternative translational CNS platform pursuing pharma collaborations, though using organoids rather than whole-brain perfusion and competing for the same partner wallet.
- Emulate: Organ-on-chip platform providing human-relevant in vitro models for pharma R&D. Comparable as a higher-fidelity alternative to animal models in CNS and other tissues, and a potential substitute buyer-side option for Bexorg's pharma customers.
Others
- Biohaven (now part of Pfizer): CNS-focused pharmaceutical company and Bexorg's flagship partner. Included as a customer/strategic counterpart rather than a competitor; provides insight into how Bexorg's anchor customer evaluates and consumes external CNS discovery platforms.
- Denali Therapeutics: Clinical-stage CNS biotech developing therapeutics for neurodegenerative diseases. Comparable as a potential customer archetype for Bexorg's platform (a CNS biotech with multiple programs needing human-brain validation), rather than a direct competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Bexorg social profiles
Digital presenceBexorg financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bexorg leadership team
Management profileNumber of profiles
Profiles6 records
Bexorg funding detail
Funding detailFunding overview
Funding rounds2 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bexorg M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bexorg
What does Bexorg do?
Bexorg operates the Brainex Platform, an integrated drug discovery system that combines the BrainEx whole-brain perfusion technology—capable of restoring molecular activity in postmortem human brains—with AI engines (NeuroScale/NeuroLens/XO Digital) that translate experimental data into predictive models. The company sells research collaboration services to pharmaceutical and biotech partners, enabling them to test therapeutics directly in physiologically intact human brain tissue to generate pharmacokinetic, pharmacodynamic, and biomarker data for CNS drug development.
Is Bexorg a public or private company?
Bexorg is a private company. It is classified as venture growth investor backed and is currently operating.
When was Bexorg founded?
Bexorg was founded in 2021. It employs 11 to 50 people.
Where is Bexorg based?
Bexorg is headquartered in San Francisco, United States, in the North America region.
How does Bexorg make money?
Two revenue lines are on record. Research Collaboration Services are the primary driver. The others are strategic Partnership Programs.
Who are Bexorg's main competitors?
Direct peers on record are Recursion Pharmaceuticals, Insitro, Atomwise and InSilico Medicine. Charles River Laboratories is listed as a broad incumbent. Emerging players are Xaira Therapeutics, Organoid Therapeutics and Emulate. Others are Biohaven (now part of Pfizer) and Denali Therapeutics.
Does Bexorg have an API?
No public API is recorded for Bexorg.
What industry is Bexorg in?
Bexorg's product category is CNS Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 2835.